p53 alterations and protein accumulation in benign breast tissue and breast cancer risk: A cohort study

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 7, 2006, Pages 1316-1323

  Rohan, Thomas E ^a   Li, Shu Qiu ^b,c   Hartwick, Robert ^b,c   Kandel, Rita A ^b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FOLDING; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR BIOPSY;

ADULT; BREAST; BREAST NEOPLASMS; CANADA; CASE-CONTROL STUDIES; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PRECANCEROUS CONDITIONS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33746460666     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0195     Document Type: Article

References (54)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88: 323-31.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408: 307-10.
3. Levine AJ, Finlay CA, Hinds PW. p53 is a tumour suppressor gene. Cell 2004;S116:S67-9.
4. Lane DP, Fischer PM. Turning the key on p53. Nature 2004;427:789-90.
5. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81-137.
6. Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 1998;58:4023-37.
7. Wang XW, Harris CC. p53 tumor-suppressor gene: clues to molecular carcinogenesis. J Cell Physiol 1997;173:247-55.
8. Kawashima K, Mihara K, Usuki H, Shimizu N, Namba M. Transfected mutant p53 gene increases X-ray-induced cell killing and mutation in human fibroblasts immortalized with 4-nitroquinoline 1-oxide but does not induce neoplastic transformation of the cells. Int J Cancer 1995;61:76-9.
9. Done SJ, Eskandarian S, Bull S, Redston M, Andrulis IL. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J Natl Cancer Inst 2001;93:700-4.
10. Tripathy D, Benz C. Activated oncogenes and putative tumor suppressor genes involved in human breast cancer. In: Oncogenes and tumor suppressor genes in human malignancies. Norwell (MA): Kluwer Academic Publishers; 1993. p. 15-60.
11. van de Vijver MJ. Molecular genetic changes in human breast cancer. In: Vande Woude GF, editor. Advances in cancer research. Vol. 61. New York: Academic Press; 1993. p. 25-56.
12. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
13. Hartmann A, Blaszyk H, Kovach JS, Sommer SS. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 1997;13: 27-33.
14. Done SJ, Arneson NCR, Ozcelik H, Redston M, Andrulis IL. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. Cancer Res 1998;58:785-9.
15. O'Malley FP, Vnencak-Jones CL, Dupont WD, Pari F, Manning S, Page DL. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. Lab Invest 1994;71: 67-72.
16. Rajan PB, Scott DJ, Perry RH, Griffith CDM. p53 protein expression in ductal carcinoma in situ (DCIS) of the breast. Breast Cancer Res Treat 1997; 42:283-90.
17. Bartek J, Bartkova J, Vojtesek B, et al. Pattern of expression of the p53 tumor suppressor gene in human breast tissues and tumors in situ and in vitro. Int J Cancer 1990;46:839-44.
18. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 1993;24:463-8.
19. Schmitt FC, Leal C, Lopes C. p53 protein expression and nuclear DNA content in breast intraductal proliferations. J Pathol 1995;176:233-41.
20. Younes M, Lebovitz RM, Bommer KE, et al. p53 protein accumulation in benign breast biopsy specimens. Hum Pathol 1995;26:155-8.
21. Lisboa BW, Vogtländer S, Gilster T, Riethdorf L, Mild-Langosch K, Löning T. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer. Virchows Arch 1997; 431:375-81.
22. Millikan R, Hulka B, Thor A, et al. p53 mutations in benign breast tissue. J Clin Oncol 1995;13:2293-300.
23. Kandel RA, Li S-Q, Ozcelik H, Rohan TE. p53 protein accumulation and mutations in normal and benign breast tissue. Int J Cancer 2000;87:73-8.
24. Guimaraes DP, Hainaut P. TP53: a key gene in human cancer. Biochimie 2002;84:83-93.
25. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996;274:2057-9.
26. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
27. Barnes DM, Hanby AM, Gillett CE, et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992;340:259-63.
28. Rohan TE, Hartwick W, Miller AB, Kandel RA. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 1998;90:1262-9.
29. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-40.
30. Dunn JM, Hastrich DJ, Newcomb P, Webb JC, Maitland NJ, Farndon JR. Correlation between p53 mutations and antibody staining in breast carcinoma. Br J Surg 1993;80:1410-2.
31. Jacquemier J, Moles JP, Penault-Llorca F, et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 1994;69:846-52.
32. Sjögren S, Inganäs M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Int 1996;88:173-82.
33. Visscher DW, Sarkar FH, Shimoyama RK, Crissman JD. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diagn Mol Pathol 1996;5:187-93.
34. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21:292-300.
35. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793-805.
36. Miller AB, Howe GR, Wall C. The national study of breast cancer screening: protocol for a Canadian randomized controlled trial of screening for breast cancer in women. Clin Invest Med 1981;4:227-58.
37. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study. I. Breast cancer detection and death rates among women aged 40 to 49 years. II. Breast cancer detection and death rates among women aged 50 to 59 years. CMAJ 1992;147:1459-88.
38. Page DL, Anderson TJ. Diagnostic histopathology of the breast. New York: Churchill Livingstone; 1987.
39. Cooper M, Li SQ, Bhardwaj T, Rohan T, Kandel RA. Evaluation of oligonucleotide arrays for sequencing of the p53 gene in DNA from formalin-fixed, paraffin-embedded breast cancer specimens. Clin Chem 2004;50:500-8.
40. Breslow NE, Day NE. Statistical methods in cancer research. Vol I. Lyon: IARC Scientific Publications No. 32; 1980.
41. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 2000;6:3923-31.
42. Fabian CJ, Kamel S, Zalles C, Kimler BF. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. J Cell Biochem 1996;25:112-22.
43. Castillo-Davis CI. The evolution of noncoding DNA: how much junk, how much func? Trends Genet 2005;21:533-6.
44. Yoshimoto T, Naruse M, Zeng Z, et al. The relatively high frequency of p53 gene mutations in multiple and malignant phaechromocytomas. J Endocrinol 1998;159:247-55.
45. Peller S, Yona R, Kopilova Y, et al. Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukaemia. Genes Chromosomes Cancer 1998;21:2-7.
46. Lehman TA, Haffty BG, Carbone CJ, et al. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res 2000;60:1062-9.
47. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophore strand conformation polymorphisms. Proc Natl Acad Sci U S A 1989;86:2766-70.
48. Kutach LS, Bolshakov S, Ananthaswamy HN. Detection of mutations and polymorphisms in the p53 tumor suppressor gene by single-strand conformation polymorphism analysis. Electrophoresis 1999;20: 1204-10.
49. Liu Q, Sommer SS. Parameters affecting the sensitivities of dideoxy fingerprinting and SSCP. PCR Methods Appl 1994;4:97-108.
50. Tolbert DM, Noffsinger AE, Miller MA, et al. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. Mod Pathol 1999;12:54-60.
51. Sato T, Yuyama Y, Watabe K, et al. Detection of p53 gene mutations in fine-needle aspiration biopsied breast cancer specimens: correlations with nuclear p53 accumulations and tumor DNA aneuploidy patterns. Cancer Lett 1997;115:47-55.
52. Gudlaugsdottir S, Sigurdardottir V, Snorradottir M, Jonasson J, Ogmundsdottir H, Eyfjord JE. p53 mutations analysis in benign and malignant breast lesions: using needle rinses from fine-needle aspirations. Diagn Cytopathol 2000;22:268-74.
53. R processed fine needle breast aspirates with surgically resected breast cancers. Mod Pathol 2000;13:1173-9.
54. Yee KS, Vousden KH. Complicating the complexity of p53. Carcinogenesis 2005;26:1317-22.